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OBJECTIVES To examine whether the Fas/Fas ligand system is involved in the pathogenesis of acute
myocardial infarction (AMI), we measured the levels of the soluble form of the Fas ligand
(sFasL) in the plasma of patients with AMI and stable or unstable angina pectoris (AP).
BACKGROUND The Fas ligand (FasL) is rapidly cleaved off by a metalloproteinase from the cell membrane
to become a soluble form as a cytokine. Fas is expressed in most cells, including
cardiomyocytes, whereas FasL is mainly expressed in inflammatory cells such as macrophages,
which are greatly accumulated in unstable plaque.
METHODS Thirty patients with AMI, 10 patients with unstable AP, 10 patients with stable AP and 30
control subjects were enrolled in the present study.
RESULTS Plasma sFasL levels were significantly elevated on hospital admission in patients with AMI
and unstable AP, compared with control subjects. Time-course studies revealed that plasma
sFasL levels rapidly decreased within 3 h and then increased again after percutaneous
transluminal coronary angioplasty in patients with AMI, but not in patients with stable AP.
Importantly, the sFasL levels were higher in the coronary sinus than in the circulation. In
addition, in vitro studies showed that the expression of FasL messenger ribonucleic acid was
upregulated in mononuclear cells isolated from patients with AMI and that hypoxia
stimulated the release of sFasL from isolated mononuclear cells.
CONCLUSIONS This demonstration of elevated levels of sFasL in patients with AMI and unstable AP
suggests that activation of the Fas/FasL system may play a pathogenic role in AMI and acute
coronary syndromes. (J Am Coll Cardiol 2002;39:585–90) © 2002 by the American
College of Cardiology
Apoptosis is an important physiologic cell death mechanism
that serves to remove damaged or unwanted cells. However,
the dysregulation of apoptosis has been implicated in many
human diseases, such as cancer, neurodegenerative diseases
and ischemic heart diseases (1). Recent studies in pathology
have shown that many cardiomyocytes die by apoptosis as
well as necrosis during myocardial infarction (2,3). Al-
though the molecular mechanism of this process is not clear,
cardiomyocyte apoptosis can be induced by many stimuli,
including hypoxia (4), ischemia/reperfusion (5), mechanical
stretch (6), tumor necrosis factor- (TNF-) (7) and
reactive oxygen species (8). Yaoita et al. (9) recently reported
that pretreatment with the caspase inhibitor ZVAD-fmk
resulted in a reduction in infarct size and an improvement of
acute functional variables in a rat model of acute myocardial
infarction (AMI). In addition, Daemen et al. (10) reported
that at the time of reperfusion, administration of the
anti-apoptotic agents insulin-like growth factor-1 and
ZVAD-fmk prevented not only renal apoptosis but also
inflammation, suggesting that the inhibition of apoptosis
may be a useful therapeutic strategy for treatment in these
ischemic animal models. However, it is not clear whether
inhibition of apoptosis is beneficial in human AMI. To
address this issue, it is necessary to define the key molecules
that regulate cardiomyocyte apoptosis during AMI.
The Fas ligand (FasL; also called the CD95 or APO-1
ligand) is a cytokine that mediates apoptosis by binding to
its receptor, Fas (also called CD95 or APO-1) through
activating caspases (11). Fas is expressed almost ubiqui-
tously in a variety of cells, including cardiomyocytes,
whereas FasL is mainly expressed in natural killer cells,
activated T cells and macrophages (12) as well as immune-
privileged tissues of the eye and testes (13). The findings
that cardiomyocytes die by apoptosis in association with
upregulation of Fas under hypoxia (14) and that FasL is
constitutively expressed in the myocardium (15) suggest that
Fas-mediated cardiomyocyte apoptosis may be involved in
the mechanism of AMI. On the other hand, Nelson et al.
(16) recently reported that the FasL transgenic heart shows
no myocardial apoptosis or necrosis but has proinflamma-
tory consequences, resulting in cardiac hypertrophy and
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fibrosis, suggesting that FasL could mediate proinflamma-
tory signals in cardiovascular diseases.
Importantly, FasL, a member of the TNF family, is
rapidly cleaved off by a metalloproteinase from the mem-
brane to become a soluble form (sFasL) as well as TNF-
(17). In human studies, sFasL has been detected in the
serum of patients with myocarditis (18) and congestive heart
failure (CHF) (19), in the cerebrospinal fluid after a severe
head injury (20) and in the bronchoalveolar lavage fluid of
patients with acute respiratory distress syndrome (21). In
contrast, Nishigaki et al. (22) reported that plasma levels of
soluble Fas, but not sFasL, were elevated in patients with
CHF. To examine the possible participation of the Fas/
FasL system in the pathogenesis of AMI, we measured the
levels of plasma sFasL in patients with AMI without CHF.
We found that plasma sFasL levels were significantly
increased in the early phases of AMI and that the levels of
sFasL were correlated with its severity.
METHODS
Subjects. We included 30 patients with AMI, 10 patients
with unstable angina pectoris (AP) and 10 patients with
stable AP. The average time from the onset of symptoms to
hospital admission was 3.5  0.4 h (range 1 to 12). All
patients with unstable AP had experienced ischemic chest
pain at rest within the preceding 48 h (i.e., Braunwald’s class
IIIB [23]), but they had no evidence of myocardial necrosis
by enzymatic criteria. Transient ST-T segment depression
or T-wave inversion, or both, were present in all patients.
Study protocol. CORONARY ANGIOGRAPHY. In all of the
30 patients with AMI, coronary angiography was performed
immediately after admission. One patient was treated with
percutaneous transluminal coronary recanalization through
intracoronary infusion of urokinase, and 29 patients were
treated with direct percutaneous transluminal coronary an-
gioplasty (PTCA). We excluded AMI patients with CHF,
concomitant inflammatory diseases, cancer or other signif-
icant heart diseases. All patients gave written, informed
consent to be included in the study, which was approved by
the Ethics Committee on Human Research of Osaka
University.
BLOOD SAMPLING AND ASSAY FOR sFasL. Blood sampling
for measuring sFasL concentrations was taken from the
peripheral vein on admission before PTCA or thrombolysis
in all patients with AMI, and in five patients it was repeated
at 3, 6, 12, 18 and 24 h after admission. In five patients with
AMI, blood samples were drawn from the coronary sinus,
using a 7F Swan-Ganz catheter, as well as from the peripheral
vein, at the same time in the same patient. The samples were
then centrifuged immediately at 3,000 rpm (4°C, 15 min) and
stored at80°C until assay. We measured the plasma levels of
sFasL by an enzyme-linked immunosorbent assay (ELISA), as
described previously (17).
MEASUREMENT OF HEMODYNAMIC VARIABLES. A Swan-
Ganz catheter was inserted into the femoral vein immedi-
ately after admission, before coronary angiography, and was
kept in place during the first two days in all patients. The
pulmonary artery wedge pressure and cardiac output in all
patients with AMI were measured by using a 7F Swan-
Ganz thermodilution catheter (Baxter Healthcare Corp.,
Santa Ana, California), and the cardiac index was calculated
as the cardiac output/body surface area ratio. Then left
ventricular end-diastolic pressure was measured by using a
5F pigtail catheter, and left ventriculography was per-
formed. The left ventricular ejection fraction was calculated
using a centerline method.
MEASUREMENT OF FasL mRNA LEVELS. Peripheral blood
mononuclear cells (PBMCs) were obtained from heparin-
ized blood by Ficoll-Paque Plus (Pharmacia LKB Biotech-
nology, Piscataway, New Jersey) gradient centrifugation.
Total ribonucleic acid (RNA) was prepared using Isogen
(Nippon Gene, Tokyo, Japan). One microgram of total
RNA was reverse transcribed in a final volume of 10 l with
200 U of Super Script II (Life Technologies, Tokyo, Japan)
containing 0.5 mmol/l of deoxynucleotide triphosphate,
10 mmol/l of dithiothreitol and 100 ng of the antisense primer
(5-GCCGAAAAACGTCTGAGATT) for human FasL.
After incubation at 42°C for 60 min, 1 l of the reaction
mixture was used for polymerase chain reaction (PCR),
which was carried out with 2.5 U of Taq deoxyribonucleic
acid (DNA) polymerase (Pharmacia) in 50 l of reaction
buffer containing 0.25 mmol/l of dNTP, 600 ng of each
sense primer (5-TGTTTCAGCTCTTCCACCTA) and
antisense primer (5-GTTCCTCATGTAGACCTTGT).
The conditions for PCR were as follows: 94°C for 1 min;
55°C for 2 min; and 72°C for 3 min, for 25 cycles with a
thermal cycler (Perkin Elmer, Norwalk, Connecticut). To
amplify human G3PDH mRNA, 100 ng of random hex-
amers (Gibco, Tokyo, Japan) was used in complementary
DNA synthesis, and 30 cycles of PCR (at 94°C for 1 min,
55°C for 2 min and 72°C for 3 min) were performed using
a commercial primer set (Clontech, Palo Alto, California).
The amplified products were subjected to electrophoresis on
1.2% agarose gels and visualized by ethidium bromide
staining. The predicted size of the FasL fragment was 344
base pairs, and that of G3PDH was 983 base pairs.
Abbreviations and Acronyms
AMI  acute myocardial infarction
AP  angina pectoris
CHF  congestive heart failure
CK-MB  creatine kinase-MB isoenzyme
ELISA  enzyme-linked immunosorbent assay
mFasL  membrane-bound Fas ligand
sFasL  soluble Fas ligand
PBMCs  peripheral blood mononuclear cells
PCR  polymerase chain reaction
PTCA  percutaneous transluminal coronary
angioplasty
TNF-  tumor necrosis factor-
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HYPOXIA EXPERIMENTS. Isolated PBMCs cultured in
serum-free Roswell Park Memorial Institute 1640 medium
were exposed for the indicated times to the ambient oxygen
concentration of 1% oxygen, 5% carbon dioxide, 94%
nitrogen at 37°C (using a controlled incubator with carbon
dioxide/oxygen monitoring and carbon dioxide/nitrogen gas
sources). The sFasL levels in the supernatant were measured
by ELISA, as described earlier.
Statistical analysis. All data are expressed as the mean
value SD. A combination of analysis of variance, based on
ranks, and a multiple comparisons procedure (i.e., the
Bonferroni/Dunn procedure) was used. A p value 0.05
was considered significant.
RESULTS
Patient characteristics. Table 1 shows the clinical charac-
teristics of the patients with stable AP, the patients with
unstable AP, the patients with AMI and the control
subjects. There were no significant differences in age or
gender ratio among these four groups. There were signifi-
cantly more hypertensive patients, smokers and diabetics in
the three groups of patients with ischemic heart disease than
in the control group.
Plasma sFasL levels on hospital admission. The plasma
sFasL levels were elevated in patients with AMI and
unstable AP on admission (3.5  0.4 h after symptom
onset), compared with the control subjects (Fig. 1). How-
ever, the sFasL levels were not elevated in patients with
stable AP.
Correlation of plasma sFasL levels with clinical variables.
Next, we examined the correlation of plasma sFasL levels
with the maximal levels of creatine kinase MB isoenzyme
(CK-MB), a marker of infarct size, and the hemodynamic
variables within the first two days after admission. There
was no significant correlation between the plasma sFasL
levels on admission and the maximal levels of CK-MB or
hemodynamic variables, such as the cardiac index (Fig. 2, A
and B).
Time course changes of plasma sFasL in patients with
AMI. To examine the physiologic significance of the mea-
surement of plasma sFasL levels, we examined the time
course of the changes of plasma sFasL levels in five patients
with AMI after admission. As shown in Figure 3A, the
plasma sFasL levels decreased rapidly within 3 h after
admission. However, they increased again after PTCA and
then returned to the basal level within 24 h. In contrast, the
sFasL levels remained high at least within 24 h after
admission in two patients with severe clinical complications
such as re-occlusion and ventricular fibrillation (data not
shown). Importantly, there was no increase in the levels of
sFasL after PTCA in patients with stable AP.
Levels of sFasL in the coronary sinus. We measured the
sFasL levels in blood samples obtained from the coronary
sinus in five patients with AMI whose culprit lesions located
at left anterior descending coronary artery, and we compared
them with those obtained from the peripheral vein at the
same time in the same patient. As shown in Figure 3B, the
level of sFasL was significantly higher in the coronary sinus
than in the peripheral vein, indicating that local concentra-
tions of sFasL may be much higher in the culprit lesion.
Expression of FasL and release of sFasL in PBMCs.
Recent pathologic studies have shown that unstable plaque
from patients with acute coronary syndromes contains many
more monocytes and macrophages, FasL-expressing cells,
compared with stable plaque (24). To address the source of
sFasL released in the circulation, we measured the levels of
FasL mRNA in PBMCs isolated from three patients with
AMI and the control subjects. As shown in Figure 4A,
FasL mRNA expression in isolated PBMCs was signifi-
cantly upregulated in a patient with AMI, compared with
control subjects. However, this upregulation disappeared
at 10 days after admission. Similar results were obtained
in two other patients with AMI. In addition, in vitro cell
culture studies showed that hypoxia (1% oxygen) signif-
icantly stimulated the release of sFasL from PBMCs
isolated from patients with AMI (Fig. 4B). These find-
ings indicate that one of the sources of sFasL could be
circulating mononuclear cells.













Age (yrs) 56  8 60  11 58  10 59  12
Men/women 21/9 6/4 7/3 23/7
Hypertension 0 3 3 10
Smoking 8 4 4 14
Diabetes mellitus 0 3 2 5
Hyperlipidemia 2 2 3 8
Data are presented as the mean value  SD or number of patients or control subjects.
AMI  acute myocardial infarction; AP  angina pectoris.
Figure 1. Plasma levels of sFasL on hospital admission in patients with
stable and unstable angina pectoris (AP) and patients with acute myocar-
dial infarction (AMI). Blood sampling for measuring the concentrations of
soluble Fas ligand (sFasL) were taken from the peripheral vein on
admission in all patients.
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DISCUSSION
In the present study, we demonstrated for the first time that
sFasL levels in the circulation were elevated at the early
phase in patients with AMI and unstable AP, compared
with control subjects.
Soluble FasL may serve as a local cytokine that induces
cardiomyocyte apoptosis during AMI. The Fas ligand, a
member of the growing TNF family, is synthesized as a type
II membrane protein that induces apoptosis in Fas-
expressing cells. The membrane-bound FasL (mFasL) can
be cleaved by a metalloproteinase to become sFasL (17,25).
Although both mFasL and secreted sFasL appear to be
biologically active, the physiologic functions of sFasL have
not been elucidated. Tanaka et al. (25) reported that sFasL
inhibits Fas-mediated lymphocyte apoptosis. However,
Brown and Savill (26) recently reported that phagocytosis
triggers macrophage release of sFasL and induces apoptosis
of bystander monocytes. Matute-Bello et al. (21) also
reported that the bronchoalveolar lavage concentration of
sFasL at the onset of acute respiratory distress syndrome
was significantly higher in patients who died and that
bronchoalveolar lavage from patients with acute respiratory
distress syndrome induced apoptosis of distal lung epithelial
cells. These observations suggest that high concentrations of
sFasL may induce apoptosis in Fas-bearing cells in a
paracrine pathway if these cells are sensitized to Fas-
mediated apoptosis (27,28). Because hypoxia has been
shown to upregulate Fas expression in cardiomyocytes and
microglial cells (14,29), cardiomyocytes may be sensitized to
Fas-mediated apoptosis during AMI. In addition, we have
shown that sFasL levels in the coronary sinus were much
higher than those in the circulation. Taken together, these
findings suggest that high local concentrations of sFasL in
the culprit lesion could facilitate cardiomyocyte apoptosis
during AMI. However, there was no significant correlation
between the plasma sFasL levels on admission and the
maximal levels of CK-MB or hemodynamic variables, such
as the cardiac index, in patients with AMI. Although the
mechanism by which plasma sFasL levels are elevated in
patients with AMI and unstable AP is not clear at present,
Figure 2. Correlation of plasma soluble Fas ligand (sFasL) levels with the maximal levels of creatine kinase-MB isoenzyme (CK-MB) (A) and with the
cardiac index (B).
Figure 3. Time course of the changes in plasma soluble Fas ligand (sFasL) levels and the differences in sFasL levels between the coronary sinus and
peripheral vein. For the time-course experiment, peripheral blood sampling was repeated at 3, 6, 12, 18 and 24 h after admission in five patients with acute
myocardial infarction (AMI) (A). Blood samples were collected from the coronary sinus and the peripheral vein at the same time in the same patient with
AMI (B). AP  angina pectoris; PTCA  percutaneous transluminal coronary angioplasty.
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it should be noted that the levels of plasma sFasL changed
rapidly after the onset of AMI (Fig. 3). Thus, it is possible
that in some patients plasma sFasL concentrations may have
already returned to the basal levels on admission, because
the time from the onset of symptoms to admission ranged
from 1 to 12 h. In addition, the levels of plasma sFasL could
rapidly increase again in response to many forms of stress,
including reperfusion (Fig. 3). Furthermore, the finding
that sFasL levels were significantly higher in the coronary
sinus than in the peripheral vein suggests that sFasL may
serve mainly as a local cytokine in culprit lesions. Taken
together, we assume that measuring the maximal levels of
sFasL in the circulation, or the levels of sFasL in the
coronary sinus, would be more appropriate ways of deter-
mining the correlation between the levels of sFasL and these
clinical variables.
Soluble FasL may serve as a proinflammatory factor. It
has been shown that FasL can induce biologic functions
unrelated to cell death, such as the induction of proinflam-
matory effects (30,31). For example, Ottonello et al. (32)
recently reported that sFasL, at concentrations incapable of
inducing cell apoptosis, has potent chemotactic properties
toward human neutrophilic polymorphonuclear leukocytes.
Seino et al. (33) also reported that the chemotactic activity
of sFasL against phagocytes is independent of the death
domain-mediated apoptosis. In addition, Nelson et al. (16)
reported that FasL expression in the heart is proinflamma-
tory, but in contrast to other examples of FasL-mediated
inflammation, the consequences appear to be mild, resulting
in hypertrophy and interstitial changes rather than tissue
destruction. Thus, it could be possible that sFasL may also
serve as a proinflammatory factor in patients with AMI and
unstable AP.
Mechanism for the elevation of plasma sFasL. The
mechanism of an increase in the plasma levels of sFasL in
patients with AMI and unstable AP is not clear at the
present time. However, we demonstrated that FasL mRNA
expression of the circulating mononuclear cells was upregu-
lated in the early phase of AMI, and it was downregulated
in the late phase, when plasma sFasL returned to the control
levels. Thus, one of the sources of sFasL could be circulating
mononuclear cells. Recent histologic studies have shown
that inflammatory cells such as monocytes and macrophages
are greatly accumulated in unstable plaque obtained from
patients with AMI and unstable AP, compared with stable
plaque (24). In the present study, the levels of sFasL in the
coronary sinus were higher than those in the circulation. In
addition, plasma sFasL levels increased again after PTCA in
the patients with AMI, but not in the patients with stable
AP. Furthermore, hypoxia stimulated the release of sFasL
from mononuclear cells isolated from patients with AMI.
Taken together, these observations suggest that mononu-
clear cells accumulated in unstable plaque may serve as a
source of sFasL in patients with AMI. On the other hand,
Wollert et al. (15) recently reported that FasL, as well as
Fas, are constitutively expressed in the rat myocardium.
Thus, hypoxia/reperfusion could stimulate the release of
sFasL from the myocardium, as well as inflammatory cells.
It has been proposed that expression of FasL by some tissues
contributes to their immune privilege status by preventing
the infiltration of inflammatory cells (13). Thus, if FasL
expression is downregulated by the conversion of mFasL to
sFasL during hypoxia/reperfusion, it could promote the
infiltration of inflammatory cells into the myocardium in
patients with AMI and unstable AP. However, further
studies are needed to clarify these points.
Conclusions. We have demonstrated that plasma sFasL
levels are elevated in patients with AMI and unstable AP
and that hypoxia stimulated the release of sFasL from
mononuclear cells isolated from patients with AMI. These
findings may provide further insights into the mechanism
underlying the pathogenesis of AMI and acute coronary
syndromes.
Figure 4. The Fas ligand (FasL) mRNA expression and soluble Fas ligand (sFasL) release in mononuclear cells isolated from patients with acute myocardial
infarction (AMI). Basal levels of FasL mRNA of mononuclear cells isolated from patients with AMI and from the control subjects (A). The mRNA from
1A12 cells (FasL-overexpressing cells) was used as a positive control. Time course changes in sFasL levels after hypoxia in the supernatant from
mononuclear cells isolated from patients with AMI (B).
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